Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Mol Pharm. 2015 May 4;12(6):2101–2111. doi: 10.1021/acs.molpharmaceut.5b00071

Table 1. Summary of size, loading content and encapsulation efficiency of different types of NPs.

Samples By Intensity (nm) By Volume (nm) PDI Loading Efficiency (μg/mg) Encapsulation Efficiency (%)
Blank NPs 75 ± 1 65 ± 1 0.073 - -
DOX-NPs 81 ± 4 62 ± 3 0.094 71.3 ± 4.7 42.8 ± 2.8
NR-NPs 80 ± 8 63 ± 2 0.106 34 ± 04 34.4 ± 4.0
DiR-NPs 83 ± 1 69 ± 1 0.133 3.1 ± 0.3 86.4 ± 8.4
Anti-CD19 Blank NPs 82 ± 1 * 68 ± 1 * 0.145 - -
Anti-CD19 DOX-NPs 83 ± 1 69 ± 1 * 0.139 72.1 ± 6.4 45.4 ± 2.1
Anti-CD19 NR-NPs 88 ± 1 75 ± 3 * 0.068 3.5 ± 0.1 35.3 ± 1.0
Anti-CD19 DiR-NPs 88 ± 1 * 73 ± 1 * 0.137 3.2 ± 0.4 89.1 ± 11.1
*

: indicates that the size of the targeted NPs is significantly larger than that of the corresponding non-targeted NPs. For example, in terms of volume, the size of anti-CD19 DOX NPs is significantly larger than that of DOX-NPs. All quantitative measurements were performed on three replicate samples. Statistical significance was evaluated using a two-tailed Student's t-test. A P value of <0.05 was considered to be statistically different.